Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), and its mass spectrometry joint-venture partner, MDS Analytical Technologies, a business unit of MDS Inc. (TSX:MDS) (NYSE:MDZ), today announced the launch of Cliquid® MPXTM-2 high-throughput workflow, an end-to-end solution for mass spectrometry users to accelerate productivity for pharmaceutical and clinical research. The Cliquid MPX workflow integrates a new software application with mass spectrometers, high-performance liquid chromatography systems and auto-samplers to uniquely increase throughput for faster results while in accordance with Good Laboratory Practice (GLP) standards of regulated markets. This can help bring new drugs to market more quickly.
The new Cliquid MPX solution addresses the need of pharmaceutical companies and clinical researchers to improve the productivity and efficiency of laboratory analysis. This solution can as much as double the throughput of Applied Biosystems/MDS Analytical Technologies QTRAP® and triple quadrupole mass spectrometers, which are widely used to analyze high volumes of samples. This increased speed enables scientists to more rapidly collect critical data that affects decisionmaking for advancing a drug candidate or conducting clinical studies. The workflow is enabled by Cliquid MPX software, which allows concurrent LC/MS/MS analysis of two streams into a single mass spectrometer with either Cliquid Software or Analyst® Software.
This is an innovation in mass spectrometry to create a single point of control for managing the complete workflow, which is supported by Applied Biosystems Global Services. This enables laboratories to increase throughput while achieving regulatory compliance by using the audit and traceability functionality of Analyst Software, providing the most efficient solution of its type within the life-science industry.
Laura Lauman, President of Life Technologies Mass Spectrometry Systems Division
"The pharmaceutical industry is under immense pressure to accelerate drugs to market. We provide the innovative tools to enable scientists to more rapidly conduct critical analyses and advance new drug candidates through the development process. The increased throughput of our industry-leading instruments, combined with the ability to integrate with third-party components, enables a unique, integrated workflow solution that will ultimately increase speed to market for new drug candidates."
Andy Boorn, President of MDS Analytical Technologies
"The Cliquid MPX workflow solution is the latest in a line of innovative software releases from the Applied Biosystems/MDS Analytical Technologies joint venture. This advancement enables an end-to-end workflow to improve laboratory analysis, while supporting the highest levels of regulatory compliance."
Overview of Cliquid Software
Overview of Analyst Software
Applied Biosystems/MDS Analytical Technologies mass spectrometers: Overview of Applied Biosystems/MDS Analytical Technologies systems
About Applied Biosystems Products
Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Applied Biosystems, along with Invitrogen - a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics - is part of Life Technologies. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world. For more information, please visit: www.appliedbiosystems.com and www.invitrogen.com.
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.